Upregulation of stomatin is associated with poor prognosis and promotes tumor progression of orbital diffuse large B-cell lymphoma

Wen Chen, Jingyi Chi, Weichen Song, Xiuyun Li, Jiaxin Ma, Xinyu Liu, Li-hua Xiao, Wenwen ZhuFrontiers in Oncology 2025 · DOI

TL;DR

Researchers have identified stomatin, a membrane protein typically associated with red blood cells, as a key driver of malignancy in orbital diffuse large B-cell lymphoma (DLBCL). High levels of stomatin correlate with significantly poorer patient survival, and experimental knockdown of the protein suggests it is a viable therapeutic target to slow tumor growth and invasion.

What Problem Does This Paper Address?

Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer. When it occurs in the orbit (the eye socket), it poses a double threat: systemic malignancy and the immediate risk of severe vision loss. While the standard "R-CHOP" chemotherapy regimen works for many, roughly 30–40% of patients experience relapse or drug resistance.

The challenge is twofold: we lack reliable biomarkers to predict which patients will have poor outcomes, and we need new molecular targets for those who don't respond to standard care. Previous research on stomatin in cancer has been contradictory—some studies labeled it a tumor suppressor, while others suggested it promotes progression. This paper seeks to clarify stomatin's role specifically within the context of orbital DLBCL.

Methods

The authors employed a "bench-to-bedside" approach combining bioinformatics, genetic epidemiology, and traditional molecular biology:

  • Bioinformatics & Mendelian Randomization (MR): To move beyond simple correlation, the team used MR analysis. By looking at genetic variants (SNPs) associated with stomatin expression in large-scale GWAS data, they could estimate whether stomatin levels causally influence DLBCL risk.
  • Clinical Validation: They analyzed 36 patients with orbital DLBCL, using immunohistochemistry (IHC) to score stomatin expression in tumor tissues and comparing it to other orbital diseases (like MALT lymphoma).
  • In Vitro Functional Assays: Using the OCI-Ly3 cell line, the researchers used siRNA to "knock down" (silence) the stomatin gene. They then measured the impact on:
  • Proliferation: Using CCK-8 assays.
  • Migration/Invasion: Using Transwell assays (measuring how well cells move through a membrane).
  • Apoptosis: Using flow cytometry to see if cells were more likely to undergo programmed cell death without stomatin.

Datasets

The study utilized several key data sources:

  • GSE83632 (GEO Database): Expression data from 76 DLBCL samples and 83 normal samples to identify differentially expressed genes.
  • OPEN GWAS Database: Specifically the finn-b-C3_DLBCL dataset, used for the Mendelian Randomization analysis to establish causality.
  • Institutional Cohort: A primary dataset of 36 orbital DLBCL patients treated between 2008 and 2014 at the Chinese PLA General Hospital and Shandong Second Medical University.

Key Insights and Ideas

  • Causality, Not Just Correlation: The Mendelian Randomization analysis provided an Odds Ratio (OR) of 1.40, suggesting that genetically predicted higher stomatin levels are associated with an increased risk of DLBCL. This suggests stomatin is a driver of the disease, not just a byproduct of it.
  • Specificity to Aggressive Subtypes: Stomatin expression was significantly higher in DLBCL compared to more indolent (slower-growing) orbital lymphomas like MALT or follicular lymphoma. This makes it a potentially specific biomarker for aggressive orbital disease.
  • A "Pro-Tumor" Switch: In this specific cancer type, stomatin acts as an oncogene. When stomatin was silenced in the lab, the cancer cells' ability to invade and migrate was "significantly weakened," and the rate of apoptosis (cell death) jumped from ~20% to ~30%.
  • Clinical Correlation: High stomatin levels were tied to higher Ann Arbor stages (more advanced disease) and higher LDH levels (a common marker of high tumor burden).

Key Results

  • Survival Impact: Patients with high stomatin expression had significantly shorter disease-free survival (DFS) and overall survival (OS). The median DFS for the whole cohort was 27.5 months, but those with high stomatin fared much worse.
  • Multivariate Analysis: After adjusting for other factors, stomatin expression remained an independent prognostic factor for survival (Relative Risk for OS = 20.186).
  • In Vitro Inhibition: Stomatin knockdown led to a significant reduction in cell proliferation within 5 days compared to control groups. It also markedly reduced the number of cells capable of migrating through Transwell membranes.

Limitations and Future Work

While the results are compelling, the authors note several hurdles:

  • Sample Size: The clinical cohort was relatively small (n=36), which is common for specific anatomical sites like the orbit but requires larger multi-center studies for validation.
  • Lack of In Vivo Data: The functional studies were limited to cell cultures (in vitro). The authors acknowledge that they have not yet validated these findings in animal models (e.g., mouse xenografts), which is a necessary step before clinical translation.
  • Mechanism of Action: The paper hints that stomatin’s role in "lipid rafts" and lipid metabolism might be the key to its pro-tumor effects, but the exact signaling pathways remain to be fully mapped.

Future research will likely focus on how stomatin interacts with the cell's metabolic machinery to promote growth and whether small-molecule inhibitors of stomatin can be developed as a novel therapy.

Summary updated

Abstract

Our findings indicate that stomatin contributes to orbital DLBCL progression and is associated with adverse clinical outcomes. Stomatin may serve as both a prognostic biomarker and a potential therapeutic target for this malignancy.
BibTeX
@inproceedings{chen2025upregulation,
  author = {Wen Chen and Jingyi Chi and Weichen Song and Xiuyun Li and Jiaxin Ma and Xinyu Liu and Li-hua Xiao and Wenwen Zhu},
  title = {{Upregulation of stomatin is associated with poor prognosis and promotes tumor progression of orbital diffuse large B-cell lymphoma}},
  booktitle = {Frontiers in Oncology},
  year = {2025},
  doi = {10.3389/fonc.2025.1596614},
}
Figure